Biopharma · FDA Approvals · Stock

CTSO Cytosorbents

CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and ot…

Assets on file: CytoSorb

Start live analysis of CTSO Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for CTSO, including recently decided ones.

October 2026

Oct 2026

~ Oct 2026

CTSOCytosorbents Corp.

CytoSorbents to Present CytoSorb Data at EACTS and ESICM Conferences in October 2026

Conference presentationCompany press releaseMonth only

Oct 2026

Oct 31, 2026

in 9 days

CTSOCytosorbents Corp.

CytoSorb: Phase 3 trial NCT04742764 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Recent first-hand events

Every first-hand event for CTSO, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Sep 30, 2026

07:00 PM

CTSOCytosorbents Corp.

CytoSorbents to Present CytoSorb Data at EACTS and ESICM Conferences in October 2026

CytoSorbents announced multiple data presentations on CytoSorb use in cardiac surgery and critical care at the EACTS Annual Meeting (Oct 7-10, 2026) and ESICM Annual Congress (Oct 10-14, 2026). Presentations draw from the COSMOS Registry and cover bleeding reduction, vasoplegia, hyperinflammation on ECMO, heart transplant outcomes, liver support, and sepsis.

Conference presentationCompany press release